Data gathered: May 30
AI Stock Analysis - Annexon (ANNX)
Analysis generated May 21, 2025. Powered by Chat GPT.
Annexon (ANNX) is a biopharmaceutical company focused on developing therapies to treat complement-mediated diseases. The company targets neurodegenerative and autoimmune disorders through its innovative approach to inhibiting C1q, the initiator of the classical complement pathway. Annexon's commitment to groundbreaking research and targeted treatment options positions it uniquely within the biopharmaceutical landscape.
Stock Alerts - Annexon (ANNX)
 |
Annexon | May 30 Price is down by -7.3% in the last 24h. |
|
Annexon | May 29 Price is up by 7.4% in the last 24h. |
|
Annexon | May 27 Price is down by -7.1% in the last 24h. |
|
Annexon | May 20 Price is up by 7.2% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Annexon
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 1 | Sign up | Sign up | Sign up |
| Sentiment | 84 | Sign up | Sign up | Sign up |
| Webpage traffic | 5,000 | Sign up | Sign up | Sign up |
| Employee Rating | 44 | Sign up | Sign up | Sign up |
| Google Trends | 40 | Sign up | Sign up | Sign up |
| Patents | 14 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 10 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 961 | Sign up | Sign up | Sign up |
| Twitter Followers | 296 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 21 | Sign up | Sign up | Sign up |
| Linkedin Employees | 121 | Sign up | Sign up | Sign up |
About Annexon
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders.
| Price | $2.12 |
| Target Price | Sign up |
| Volume | 207,150 |
| Market Cap | $223M |
| Year Range | $1.38 - $7.63 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Annexon Biosciences to Present at the Jefferies Global Healthcare ConferenceMay 29 - Yahoo |
|
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual MeetingMay 19 - Yahoo |
Annexon Reports Inducement Grants to New Employees under Nasdaq Listing Rule 5635(4)May 18 - Finnhub |
|
 |
What is HC Wainwright’s Estimate for Annexon Q2 Earnings?May 17 - ETF Daily News |
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)May 16 - GlobeNewswire |
|
Annexon Reports Inducement Grants To New Employees Under Nasdaq Listing Rule 5635(C)(4)May 16 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 0 | 0 | 0 | -54M | -57M | -0.370 |
| Q4 '24 | 0 | 0 | 0 | -49M | -52M | -0.330 |
| Q3 '24 | 0 | 0 | 0 | -35M | -39M | -0.250 |
| Q2 '24 | 0 | 860,000 | -860,000 | -30M | -33M | -0.230 |
| Q1 '24 | 0 | 850,000 | -850,000 | -25M | -28M | -0.210 |
Insider Transactions View All
| Lew Jennifer filed to sell 77,770 shares at $2.9. February 20 '25 |
| Overdorf Michael filed to sell 86,579 shares at $3. February 20 '25 |
| Yednock Ted filed to sell 61,237 shares at $2.9. February 20 '25 |
| ARTIS DEAN RICHARD filed to sell 83,814 shares at $3. February 20 '25 |
| Dananberg Jamie filed to sell 33,479 shares at $3. February 20 '25 |
Similar companies
Read more about Annexon (ANNX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Annexon?
The Market Cap of Annexon is $223M.
What is the current stock price of Annexon?
Currently, the price of one share of Annexon stock is $2.12.
How can I analyze the ANNX stock price chart for investment decisions?
The ANNX stock price chart above provides a comprehensive visual representation of Annexon's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Annexon shares. Our platform offers an up-to-date ANNX stock price chart, along with technical data analysis and alternative data insights.
Does ANNX offer dividends to its shareholders?
As of our latest update, Annexon (ANNX) does not offer dividends to its shareholders. Investors interested in Annexon should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Annexon?
Some of the similar stocks of Annexon are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.